Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Increases By 77.6%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 489,633 shares, a growth of 77.6% from the April 15th total of 275,689 shares. Based on an average daily trading volume, of 681,214 shares, the short-interest ratio is presently 0.7 days. Currently, 8.6% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

ALGS has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. Wall Street Zen raised Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday. Finally, Westpark Capital began coverage on Aligos Therapeutics in a research report on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Aligos Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.50.

Aligos Therapeutics Trading Down 6.1%

Shares of ALGS opened at $5.36 on Tuesday. The firm has a market cap of $33.18 million, a PE ratio of -0.62 and a beta of 2.28. The firm has a fifty day simple moving average of $7.00 and a two-hundred day simple moving average of $7.98. Aligos Therapeutics has a 1-year low of $5.12 and a 1-year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.29) by $0.08. The firm had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. As a group, research analysts forecast that Aligos Therapeutics will post -7.54 EPS for the current fiscal year.

Institutional Trading of Aligos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALGS. Geode Capital Management LLC boosted its stake in shares of Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after acquiring an additional 5,978 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares in the last quarter. SummitTX Capital L.P. raised its holdings in Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after purchasing an additional 9,375 shares during the period. NorthCrest Asset Manangement LLC purchased a new position in Aligos Therapeutics during the third quarter valued at $98,000. Finally, Susquehanna International Group LLP purchased a new position in Aligos Therapeutics during the third quarter valued at $99,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.